RedHill Biopharma (RDHL) Net Cash Flow (2016 - 2022)

RedHill Biopharma has reported Net Cash Flow over the past 11 years, most recently at -$2.4 million for Q4 2022.

  • Quarterly Net Cash Flow fell 189.24% to -$2.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$2.4 million through Dec 2023, up 87.4% year-over-year, with the annual reading at $121000.0 for FY2025, 112.09% up from the prior year.
  • Net Cash Flow was -$2.4 million for Q4 2022 at RedHill Biopharma, up from -$6.0 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $48.5 million in Q1 2020 and troughed at -$59.4 million in Q2 2020.
  • The 5-year median for Net Cash Flow is -$5.4 million (2020), against an average of -$1.4 million.
  • Year-over-year, Net Cash Flow skyrocketed 727.8% in 2020 and then plummeted 818.99% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at $10.2 million in 2018, then surged by 118.77% to $22.2 million in 2019, then plummeted by 121.43% to -$4.8 million in 2020, then skyrocketed by 156.96% to $2.7 million in 2021, then tumbled by 189.24% to -$2.4 million in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Net Cash Flow are -$2.4 million (Q4 2022), -$6.0 million (Q3 2022), and -$1.7 million (Q2 2022).